TrialNature communications2025

Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.

Jing Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.